XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.23.2

Other Income | 9 Months Ended
--- | ---
Jun. 30, 2023
Other Income |
Other Income | Note 3 Other Income Grant Income As of June 30, 2023, the Company had received $995,862 in a research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX®2-73 related to Parkinson’s disease. Of the total, $497,931 was received during the nine months ended June 30, 2023, and $497,931 was received during the year ended September 30, 2021. The grant income was recorded to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are incurred. During the three and nine months ended June 30, 2023, the Company recognized $0 and $25,000, respectively (2022: $0 and $0, respectively) of this grant on its statements of operations as grant income. At June 30, 2023, an amount of $916,763 (September 30, 2022: $443,831) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset the income. Research and development incentive income Research and development incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the “Tax Incentive Credit”). During the three and nine months ended June 30, 2023, the Company recorded research and development incentive income of $564,842 (AUD 852,862) and $2,048,113 (AUD 3,068,615), respectively (2022: $682,432 (AUD 954,986) and $2,328,675 (AUD 3,218,303), respectively) in respect of the Tax Incentive Credit for eligible research and development expenses incurred during the period. The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject to pre-issue review or audit by the ATO and the ATO may have different interpretations of certain eligibility requirements. Currently, the Company’s tax incentive claims from 2019 to 2022 are open to potential review or audit by the ATO.

X
- References No definition available. + Details
Name: | avxl_DisclosureOtherIncomeAbstract
Namespace Prefix: | avxl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | avxl_OtherIncomeDisclosureTextBlock
Namespace Prefix: | avxl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration